Home / Business and Economy / Wiley Partners with IQVIA for Streamlined Clinical Trials
Wiley Partners with IQVIA for Streamlined Clinical Trials
9 Dec, 2025
Summary
- Wiley and IQVIA formed a partnership for COA execution.
- The collaboration simplifies complex COA licensing and implementation.
- Phase one offers five Wiley COA tools as complete solutions.
John Wiley & Sons, Inc. has entered a significant partnership with IQVIA Holdings Inc. aimed at simplifying Clinical Outcome Assessment (COA) execution. This collaboration addresses the historically complex and time-consuming process of COA licensing, which usually requires managing multiple vendors for instruments, translation, and implementation.
The new integrated solution provides pharmaceutical and research organizations with a streamlined, single-contract approach. This simplifies workflows, enhances quality assurance, and ensures scientific accuracy and copyright protection, significantly reducing potential trial delays and compliance issues.
Phase one of this initiative offers five Wiley-managed COA tools as complete packages. The plan is to broaden this offering by the end of 2026 to include Wiley's extensive catalog of over 100 COAs, complete with full lifecycle services.
